Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 15/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.56 |
| ▸ | PDE4A | P27815 | 15/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5504845 | 0.99 | PDE4D (0.56) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL5505673 | 0.90 | PDE4D (0.54) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL72937 | 0.89 | PDE4D (0.69) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL75217 | 0.88 | PDE4D (0.68) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL75216 | 0.88 | PDE4D (0.68) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| Revamilast SCHEMBL19205850 | 0.83 | PDE4D (0.59) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL73200 | 0.79 | PDE4D (0.67) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL5017912 | 0.79 | PDE4B (0.71) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL73641 | 0.78 | PDE4D (0.66) | PDE4DPDE4BPDE4APDE4CABCB11 | |
| SCHEMBL74217 | 0.77 | PDE4B (0.63) | PDE4DPDE4BPDE4APDE4CNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012110946-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE PDE4 ENZYME INHIBITOR REVAMILAST AND A DISEASE MODIFYING AGENT, PREFERABLY METHOTREXATE | GLENMARK PHARMACEUTICALS SA (CH) | 2012-08-23 | — | — | WO | claimed |
| EP-1831227-A2 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | Glenmark Pharmaceuticals S.A. (CH) | 2007-09-12 | — | — | EP | claimed |
| WO-2006064355-A2 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-06-22 | — | — | WO | claimed |
| WO-2012110946-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE PDE4 ENZYME INHIBITOR REVAMILAST AND A DISEASE MODIFYING AGENT, PREFERABLY METHOTREXATE | GLENMARK PHARMACEUTICALS SA (CH) | 2012-08-23 | — | — | WO | disclosed |
| WO-2008142542-A2 | PROCESSES FOR PREPARING BENZOFURO [3, 2-C] PYRIDINE- 9-CARBALDEHYDE DERIVATIVES AS NOVEL INTERMEDIATES FOR THE SYNTHESIS OF PDE IV INHIBITORS | GLENMARK PHARMACEUTICALS, S.A. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008093221-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PDE4 INHIBITOR FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS, S.A. (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008081282-A2 | PROCESS FOR THE SYNTHESIS OF N9-(3,5-DICHLORO-4-PYRIDYL)-6- DIFLUOROMETHOXYBENZO(4,5)FURO(3,2-C)PYRIDINE-9-CARBOXAMIDE AND SALTS THEREOF | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-1831227-A2 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | Glenmark Pharmaceuticals S.A. (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006064355-A2 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-06-22 | — | — | WO | disclosed |